Gabapentin Market: Global Industry Analysis and Forecast (2024-2030)

  • The Gabapentin Market size was valued at USD 2.32 Bn. in 2023 and the total Global Gabapentin revenue is expected to grow at a CAGR of 5.4% from 2024 to 2030, reaching nearly USD 3.36 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2072

Gabapentin Market Overview

Gabapentin, a gamma-aminobutyric acid (GABA) analog, is a widely prescribed anticonvulsant and neuropathic pain medication. The global gabapentin market has seen substantial growth in recent years, driven by the increasing prevalence of neurological disorders, such as epilepsy, neuropathic pain, and restless leg syndrome. Gabapentin's ability to modulate the activity of certain neurotransmitters and its favorable safety profile has contributed to its widespread adoption in various therapeutic areas, including the management of post-herpetic neuralgia, diabetic neuropathy, and fibromyalgia.

 

  • According to SMR, In the United States, more than 300,000 people with epilepsy are younger than 14 and more than 500,000 are older than 65.

 

The gabapentin market is highly competitive, with the presence of generic manufacturers offering cost-effective alternatives to branded formulations. The patent expiration of branded gabapentin products has paved the way for generic competition, resulting in price erosion and increased accessibility for patients. Key players in the market include Pfizer, Mylan, Teva Pharmaceutical Industries, Novartis, and GlaxoSmithKline, among others. Strategic collaborations, mergers and acquisitions, and the development of novel formulations and delivery systems are expected to shape the competitive landscape.

 

The Asia-Pacific region is projected to be the fastest-growing market for gabapentin during the forecast period. This growth is attributed to the rising geriatric population, increasing healthcare expenditure, and the growing prevalence of neurological disorders in countries such as China, India, and Japan. Besides, the region's large patient pool and improving healthcare infrastructure are expected to drive the demand for gabapentin shortly. Initiatives by governments and healthcare organizations to raise awareness about neurological conditions and improve access to effective treatment options are also contributing to the market's growth in this region.

 

  • According to SMR, India exports most of its Gabalapentin to the United States, Singapore, and the United Kingdom

Gabapentin Market

 

To get more Insights: Request Free Sample Report

 

Gabapentin Market Dynamics

The increasing application of gabapentin in neuropathic pain treatment is owing to the rising global incidence of neuropathic pain.

The gabapentin market has witnessed substantial growth, primarily driven by its increasing application in neuropathic pain treatment. As the global incidence of neuropathic pain rises, attributed to factors such as an aging population and a high prevalence of chronic diseases, the demand for effective treatment options like gabapentin is escalating. Approximately 7% to 10% of the general population suffers from neuropathic pain, with this figure expected to climb to 20% to 30% among individuals with diabetes in the U.K. This surge underscores the pharmaceutical industry's focus on developing and distributing gabapentin to meet growing healthcare needs. The availability of generic versions has significantly enhanced accessibility, making this crucial medication more affordable and broadening its market reach.

 

Beyond neuropathic pain, gabapentin's utility in off-label indications is another potent demand driver in the pharmaceutical industry. It is increasingly prescribed for conditions such as anxiety disorder, bipolar disorder, and insomnia, expanding its application spectrum. Supportive reimbursement policies in various countries further bolster market growth by reducing financial barriers for patients. Also, heightened awareness among healthcare professionals and patients about gabapentin's efficacy, coupled with the development of new, more user-friendly formulations, fuels its adoption. These multifaceted factors collectively drive the robust expansion of the gabapentin market, making it a pivotal component of contemporary pain management and psychiatric treatment paradigms.

 

  • For instance, the UK National Health Service (NHS) reported an increase in prescriptions for generic gabapentin, highlighting its widespread acceptance and affordability
  • Gabapentinoid users increased from 4.0% in 2015 to 4.7% in 2021, Medical Expenditure Panel Survey (MEPS) data showed. Gabapentinoids which include gabapentin and pregabalin continued to be used for chronic pain.
  • According to SMR analysis, transient inflammatory pain causes lasting changes in sensory neurons, predisposing individuals to chronic pain.

Gabapentin Market1

Regulatory Scrutiny and Safety Concerns

Despite its growing popularity, the gabapentin market faces significant restraints that hinder its growth. A major concern is the increasing scrutiny and regulation surrounding the drug's off-label use. The FDA and other regulatory bodies have issued warnings regarding the potential risks of misuse and dependence associated with gabapentin, leading to tighter prescribing practices and monitoring requirements

 

  • For instance, a 2023 FDA alert highlighted the rising incidence of gabapentin abuse, prompting healthcare providers to exercise greater caution in its prescription.

 

The National Institutes of Health (NIH) has raised concerns about the drug's side effects, including dizziness, drowsiness, and respiratory issues, particularly when combined with other medications. These safety issues have led to a more cautious approach among physicians and patients, potentially dampening market growth. Legal actions and class-action lawsuits related to gabapentin's side effects and off-label promotion have created a more challenging environment for its manufacturers, affecting their market strategies and financial performance.                                                   

 

Technological Advancements in Drug Delivery

Innovations in drug delivery systems present an opportunity in the gabapentin market, particularly in enhancing drug efficacy and patient compliance. Advances such as extended-release formulations and transdermal patches improve the convenience and effectiveness of gabapentin in treating conditions like neuropathic pain and epilepsy. These innovations ensure a steady release of the medication, reducing the frequency of doses and minimizing side effects, thereby fostering greater patient adherence to treatment regimens.

 

Companies like Pfizer are leading the way with new formulations, such as PD-217,014, which are specifically designed to optimize therapeutic outcomes. These advanced delivery systems also cater to the growing demand for more user-friendly and efficient treatments, supporting the overall market growth. With these technological advancements, pharmaceutical companies significantly enhance the adoption of gabapentin, ensuring better patient outcomes and expanding their market share in the epilepsy and neuropathic pain treatment sectors.              

                                 

Fig 1. Types of recent drug delivery systems for different therapeutic purposes

Gabapentin Market2

DDS- Drug Delivery System

Gabapentin Market Segment Analysis

Based on the Route of Administration, the oral segment held the largest market share in the Gabapentin Market in 2023. According to the SMR analysis, the segment is expected to grow during the forecast period and maintain its dominance till 2030. The oral route of administration emerges as the leading segment in the gabapentin market, dominating in terms of usage and revenue generation. This preference for oral administration is attributed to several factors, including patient convenience, ease of administration, and the availability of various oral formulations of gabapentin.

 

Patients suffering from neuropathic pain, epilepsy, and other related conditions often prefer oral medications due to their familiarity and comfort with this administration route. Pharmaceutical companies have responded to this demand by developing a wide range of oral gabapentin formulations, including tablets, capsules, and oral solutions, catering to diverse patient needs and preferences.

 

The oral route offers healthcare providers flexibility in dosing and titration, enabling personalized treatment plans tailored to individual patient requirements. This versatility contributes to the widespread adoption of oral gabapentin across various medical settings, solidifying its position as the primary route of administration in the gabapentin market.

Gabapentin Market3

Gabapentin Market Regional Analysis

North America dominated the gabapentin industry with the largest revenue share in 2023 and is expected to maintain its dominant position, in terms of share, throughout the forecast period. North America stands as the leading market for gabapentin, showcasing robust growth and market dominance driven by factors such as the increasing prevalence of neuropathic pain conditions, rising awareness about gabapentin's therapeutic benefits, and advancements in drug delivery systems. The medication is used to treat anxiety, bipolar disorder, nausea, and other off-label indications. It is high in demand in the United States and Canada from this region

 

  • According to The U.S. Food and Drug Administration (FDA), gabapentin prescriptions have been steadily increasing in the region, reflecting its growing acceptance and usage among healthcare providers and patients.

 

Import and export trends indicate a significant flow of gabapentin products within North America, further cementing its position as a key market.

 

  • For example, pharmaceutical companies like Pfizer, Teva, and Mylan have been actively exporting gabapentin formulations to meet the rising demand in the region.

 

Supportive reimbursement policies and regulatory initiatives in countries like the United States and Canada have contributed to the market's growth by ensuring the affordability and accessibility of gabapentin medications. North America's leading position in the gabapentin market underscores its vital role in driving innovation and growth within the pharmaceutical industry.

Gabapentin Market3

Gabapentin Market Competitive Landscape

In the competitive landscape of the gabapentin market, pharmaceutical companies vie for market share. Leading players such as Pfizer, Teva Pharmaceutical Industries, Mylan N.V., Sun Pharmaceutical Industries, and Apotex Inc. dominate the global market with their extensive product portfolios and strong distribution networks. These companies focus on strategic initiatives such as product launches, mergers and acquisitions, and partnerships to strengthen their market position and expand their geographical presence.

 

The market witnesses competition from generic drug manufacturers offering cost-effective alternatives to brand-name gabapentin medications. The competitive dynamics are further influenced by factors such as patent expirations, regulatory approvals, and advancements in drug formulations. Continuous investments in research and development to enhance drug efficacy and minimize side effects remain pivotal for companies seeking to gain a competitive edge in the gabapentin market.

 

  • June 23, 2023, In the US, Lupin introduces an oral suspension for the treatment of seizure disorders.
  • In 2022 Laurus Labs Limited (India) proclaimed the successful commercialization of Gabapentin API (Active Pharmaceutical Ingredient) in various markets.
  • Mar 15, 2021, Alkem Laboratories has launched Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India.
  • In 2021 - Aurobindo Pharma Limited (India) declared the launch of Gabapentin Capsules in the U.S. market, a generic version of Neurontin® Capsules.
  • In September 2021, Pfizer confirmed the acquisition of a privately held company, Amplyx Pharmaceuticals, focused on developing treatments for life-threatening infections.
  • In 2021, Teva declared the launch of a generic version of gabapentin in the United States.
  • In 2021, Alembic Pharmaceuticals Inc. (U.S.) Launched Gabapentin Tablets in the U.S. market after receiving final approval from the FDA.
  • In 2021, Apotex Inc. (Canada) Launched Gabapentin Capsules in the U.S. market after receiving final approval from the FDA.
  • In 2020, Mylan declared the launch of a generic version of gabapentin in the United States.

 

Gabapentin Market Scope

Gabapentin Market

Market Size in 2023

USD 2.32Bn.

Market Size in 2030

USD 3.36  Bn.

CAGR (2024-2030)

5.4 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

Segments

By Product Type

Capsule

Tablet

Oral Solution

By Route of Administration

Oral

Parenteral

By Application

Epilepsy

Neuropathic Pain

Restless Legs Syndrome

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Scope

North America(United States), Canada, and Mexico

Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Key Players in the Gabapentin Market

  1. Pfizer Inc. (U.S.)
  2. Teva Pharmaceutical Industries Ltd. (Israel)
  3. Hikma Pharmaceuticals PLC (Jordan)
  4. Sun Pharmaceutical Industries Ltd. (India)
  5. Aurobindo Pharma Limited (India)
  6. Dr. Reddy's Laboratories Ltd. (India)
  7. Lupin Limited (India)
  8. Torrent Pharmaceuticals Ltd. (India)
  9. Glenmark Pharmaceuticals Ltd. (India)
  10. Zydus Cadila (India)
  11. Cipla Ltd. (India)
  12. Alembic Pharmaceuticals Limited (India)
  13. Jubilant Life Sciences Limited (India)
  14. Laurus Labs Limited (India)
  15. Accord Healthcare Inc. (U.K.)
  16. Apotex Inc. (Canada)
  17. Sandoz International GmbH (Switzerland)
  18. Glenmark Pharmaceuticals Inc. (U.S.)
  19. Accord Healthcare B.V. (Netherlands)
  20. Intas Pharmaceuticals Ltd. (India)
  21. Alembic Pharmaceuticals Inc. (U.S.)
  22. Torrent Pharma Inc. (U.S.)
  23. Alkem Laboratories Ltd. (India)
  24. XXX.Inc.


Frequently Asked Questions

The Gabapentin Market is expected to grow at a CAGR of 5.4 % during the forecast period of 2023 to 2030.

1.    Gabapentin Market: Research Methodology 
2.    Gabapentin Market: Executive Summary
3.    Gabapentin Market: Competitive Landscape

3.1. Stellar Competition Matrix
3.2. Competitive Landscape
3.3. Key Players Benchmarking
3.4. Market Structure
3.4.1.    Market Leaders 
3.4.2.    Market Followers
3.4.3.    Emerging Players

3.5. Consolidation of the Market
3.6. Global Import-Export Analysis
4.    Gabapentin Market: Dynamics
4.1. Market Driver 
4.2. Market Trends 
4.3. Market Restraints
4.4. Market Opportunities
4.5. Market Challenges
4.6. PORTER’s Five Forces Analysis
4.7. PESTLE Analysis
4.8. Strategies for New Entrants to Penetrate the Market
4.9. Regulatory Landscape by Region
4.9.1.    North America
4.9.2.    Europe
4.9.3.    Asia Pacific
4.9.4.    Middle East and Africa
4.9.5.    South America

5.    Gabapentin Market Size and Forecast by Segments (by Value in USD Billion)
5.1. Gabapentin Market Size and Forecast, by Product Type (2023-2030)
5.1.1.    Capsule
5.1.2.    Tablet
5.1.3.    Oral Solution 

5.2. Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
5.2.1.    Oral
5.2.2.    Parenteral 

5.3. Gabapentin Market Size and Forecast, by Application (2023-2030)
5.3.1.    Epilepsy
5.3.2.    Neuropathic Pain
5.3.3.    Restless Legs Syndrome
5.3.4.    Others 

5.4. Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
5.4.1.    Hospital Pharmacies
5.4.2.    Retail Pharmacies
5.4.3.    Online Pharmacies 

5.5. Gabapentin Market Size and Forecast, by Region (2023-2030)
5.5.1.    North America
5.5.2.    Europe
5.5.3.    Asia Pacific
5.5.4.    Middle East and Africa
5.5.5.    South America

6.    North America Gabapentin Market Size and Forecast (by Value in USD Billion)
6.1. North America Gabapentin Market Size and Forecast, by Product Type  (2023-2030)
6.1.1.    Capsule
6.1.2.    Tablet
6.1.3.    Oral Solution

6.2.  North America Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
6.2.1.    Oral
6.2.2.    Parenteral 

6.3. North America Gabapentin Market Size and Forecast, by Application (2023-2030)
6.3.1.    Epilepsy
6.3.2.    Neuropathic Pain
6.3.3.    Restless Legs Syndrome
6.3.4.    Others 

6.4. North America Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
6.4.1.    Hospital Pharmacies
6.4.2.    Retail Pharmacies
6.4.3.    Online Pharmacies 

6.5. North America Gabapentin Market Size and Forecast, by Country (2023-2030)
6.5.1.    United States
6.5.2.    Canada
6.5.3.    Mexico

7.    Europe Gabapentin Market Size and Forecast (by Value in USD Billion )
7.1. Europe Gabapentin Market Size and Forecast, by Product Type  (2023-2030)
7.1.1.    Capsule
7.1.2.    Tablet
7.1.3.    Oral Solution

7.2.  Europe Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
7.2.1.    Oral
7.2.2.    Parenteral 

7.3. Europe Gabapentin Market Size and Forecast, by Application (2023-2030)
7.3.1.    Epilepsy
7.3.2.    Neuropathic Pain
7.3.3.    Restless Legs Syndrome
7.3.4.    Others 

7.4. Europe Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
7.4.1.    Hospital Pharmacies
7.4.2.    Retail Pharmacies
7.4.3.    Online Pharmacies 

7.5. Europe Gabapentin Market Size and Forecast, by Country (2023-2030)
7.5.1.    UK
7.5.2.    France
7.5.3.    Germany
7.5.4.    Italy
7.5.5.    Spain
7.5.6.    Sweden
7.5.7.    Austria
7.5.8.    Rest of Europe

8.    Asia Pacific Gabapentin Market Size and Forecast (by Value in USD Billion )
8.1. Asia Pacific Gabapentin Market Size and Forecast, by Product Type  (2023-2030)
8.1.1.    Capsule
8.1.2.    Tablet
8.1.3.    Oral Solution

8.2.  Asia Pacific Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
8.2.1.    Oral
8.2.2.    Parenteral 

8.3. Asia Pacific  Gabapentin Market Size and Forecast, by Application (2023-2030)
8.3.1.    Epilepsy
8.3.2.    Neuropathic Pain
8.3.3.    Restless Legs Syndrome
8.3.4.    Others 

8.4. Asia Pacific Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
8.4.1.    Hospital Pharmacies
8.4.2.    Retail Pharmacies
8.4.3.    Online Pharmacies 

8.5. Asia Pacific Gabapentin Market Size and Forecast, by Country (2023-2030)
8.5.1.    China
8.5.2.    S Korea
8.5.3.    Japan
8.5.4.    India
8.5.5.    Australia
8.5.6.    Indonesia 
8.5.7.    Malaysia
8.5.8.    Vietnam
8.5.9.    Taiwan
8.5.10.    Bangladesh 
8.5.11.    Pakistan
8.5.12.    Rest of Asia Pacific

9.    Middle East and Africa Gabapentin Market Size and Forecast (by Value in USD Billion )
9.1. Middle East and Africa Gabapentin Market Size and Forecast, by Product Type  (2023-2030)
9.1.1.    Capsule
9.1.2.    Tablet
9.1.3.    Oral Solution

9.2.  Middle East and Africa Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
9.2.1.    Oral
9.2.2.    Parenteral 

9.3. Middle East and Africa Gabapentin Market Size and Forecast, by Application (2023-2030)
9.3.1.    Epilepsy
9.3.2.    Neuropathic Pain
9.3.3.    Restless Legs Syndrome
9.3.4.    Others 

9.4. Middle East and Africa Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
9.4.1.    Hospital Pharmacies
9.4.2.    Retail Pharmacies
9.4.3.    Online Pharmacies 

9.5. Middle East and Africa Single-Use Filtration Assembly Market Size and Forecast, by Country (2023-2030)
9.5.1.    South Africa
9.5.2.    GCC
9.5.3.    Egypt
9.5.4.    Nigeria
9.5.5.    Rest of ME&A

10.    South America Gabapentin Market Size and Forecast (by Value in USD Billion )
10.1. South America Gabapentin Market Size and Forecast, by Product Type  (2023-2030)
10.1.1.    Capsule
10.1.2.    Tablet
10.1.3.    Oral Solution

10.2.  South America Gabapentin Market Size and Forecast, by Route of Administration (2023-2030)
10.2.1.    Oral
10.2.2.    Parenteral 

10.3. South America Gabapentin Market Size and Forecast, by Application (2023-2030)
10.3.1.    Epilepsy
10.3.2.    Neuropathic Pain
10.3.3.    Restless Legs Syndrome
10.3.4.    Others 

10.4. South America Gabapentin Market Size and Forecast, by Distribution Channel (2023-2030)
10.4.1.    Hospital Pharmacies
10.4.2.    Retail Pharmacies
10.4.3.    Online Pharmacies 

10.5. South America Gabapentin Market Size and Forecast, by Country (2023-2030)
10.5.1.    Brazil
10.5.2.    Argentina
10.5.3.    Rest of South America

11.    Company Profile: Key players
11.1. Pfizer Inc. 
11.1.1.    Company Overview
11.1.2.    Financial Overview
11.1.3.    Business Portfolio
11.1.4.    SWOT Analysis
11.1.5.    Business Strategy 
11.1.6.    Recent Developments

11.2.  Teva Pharmaceutical Industries Ltd.
11.3. Hikma Pharmaceuticals PLC
11.4. Sun Pharmaceutical Industries Ltd.
11.5. Aurobindo Pharma Limited
11.6. Dr. Reddy's Laboratories Ltd.
11.7. Lupin Limited
11.8. Torrent Pharmaceuticals Ltd.
11.9. Glenmark Pharmaceuticals Ltd.
11.10. Zydus Cadila
11.11. Cipla Ltd.
11.12. Alembic Pharmaceuticals Limited
11.13. Jubilant Life Sciences Limited
11.14. Laurus Labs Limited
11.15. Accord Healthcare Inc.
11.16. Apotex Inc.
11.17. Sandoz International GmbH
11.18. Glenmark Pharmaceuticals Inc.
11.19. Accord Healthcare B.V.
11.20. Intas Pharmaceuticals Ltd.
11.21. Alembic Pharmaceuticals Inc.
11.22. Torrent Pharma Inc.
11.23. Alkem Laboratories Ltd.
11.24 XXX.Inc
12.    Key Findings
13.    Industry Recommendations 

Enquiry Before Buy


Request Sample PDF